Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Acellular Pertussis
- Sponsor
- GlaxoSmithKline
- Enrollment
- 657
- Locations
- 1
- Primary Endpoint
- Number of Seroprotected Subjects for Anti-poliovirus Type 1, 2 and 3
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the booster vaccine dose of 2 new formulations of DTPa-HBV-IPV/Hib administered between 12 and 15 months of age, and the immune persistence following the primary series. All children in this booster study received a primary vaccination at 2, 3 and 4 months of age in study 113948 (NCT01248884). No new subjects will be enrolled in this booster study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects who participated in the study 113948 (NCT01248884) and received three doses of the new or licensed DTPa-HBV-IPV/Hib study vaccine.
- •A male or female child between, and including, 12 and 15 months of age at the time of the booster vaccination.
- •Subjects who the investigator believes that parent(s)/ Legally Acceptable Representative(s) (LAR(s)) can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visit).
- •Written informed consent obtained from the parent(s)/LAR(s) of the subject.
- •Healthy subjects as established by medical history and clinical examination before entering into the study.
Exclusion Criteria
- •Child in care.
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the booster dose of study vaccine, or planned use during the study period.
- •Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose.
- •Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during the study period.
- •Participation in another clinical study within three months prior to enrolment in the present booster study or at any time during the present booster study, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- •Evidence of previous or intercurrent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Hib vaccination or disease since the conclusion visit of study 113948 (NCT01248884).
- •Serious chronic illness.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.
- •History of any neurological disorders or seizures.
Outcomes
Primary Outcomes
Number of Seroprotected Subjects for Anti-poliovirus Type 1, 2 and 3
Time Frame: 1 month post booster vaccination (POST) (subjects enrolled after protocol amendment 2)
A seroprotected subject was a subject whose antibody titre was greater than or equal to the level defining clinical protection of 8.
Number of Seroprotected Subjects Against Anti-HBs Antigens
Time Frame: 1 month post booster vaccination (POST) (subjects enrolled after protocol amendment 2)
A seroprotected subject was a subject whose antibody concentration was greater than or equal to the level defining clinical protection of 10 milli-international units per millilitre (mIU/mL).
Number of Seroprotected Subjects for Anti-polyribosyl-ribitol Phosphate (Anti-PRP)
Time Frame: 1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2)
A seroprotected subject was defined as a vaccinated subject who had anti-PRP antibody concentrations ≥ 0.15 micrograms per milliliter (µg/mL).
Number of Seroprotected Subjects Against Anti-Hepatitis B (Anti-HBs) Antigens
Time Frame: 1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2)
A seroprotected subject was a subject whose antibody concentration was greater than or equal to the level defining clinical protection of 10 milli-international units per millilitre (mIU/mL).
Number of Seroprotected Subjects for Anti-poliovirus Types 1, 2 and 3
Time Frame: 1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2)
A seroprotected subject was a subject whose antibody titre was greater than or equal to the level defining clinical protection of 8.
Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies
Time Frame: 1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2)
A seroprotected subject was defined as a vaccinated subject who had anti-D and anti-T antibody concentrations ≥ 0.1 international units per milliliter (IU/mL).
Number of Seroprotected Subjects for Anti-D and Anti-T Antibodies
Time Frame: 1 month post booster vaccination (POST) (subjects enrolled after protocol amendment 2)
A seroprotected subject was defined as a vaccinated subject who had anti-D and anti-T antibody concentrations ≥ 0.1 international units per milliliter (IU/mL).
Number of Seroprotected Subjects for Anti-PRP
Time Frame: 1 month post booster vaccination (POST) (subjects enrolled after protocol amendment 2)
A seroprotected subject was defined as a vaccinated subject who had anti-PRP antibody concentrations ≥ 0.15 micrograms per milliliter (µg/mL).
Concentrations for Anti-Pertussis Toxoid (Anti-PT), Anti-Filamentous Haemagglutinin (Anti-FHA), Anti-Pertactin (Anti-PRN)
Time Frame: 1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2)
Concentrations were expressed as geometric mean concentrations (GMCs). Seropositivity cut-off assay was 5 EL.U/mL.
Concentrations for Anti-PT, Anti-FHA and Anti-PRN
Time Frame: 1 month post booster vaccination (subjects enrolled after protocol amendment 2)
Concentrations were expressed as geometric mean concentrations (GMCs). Seropositivity cut-off assay was 5 EL.U/mL.
Secondary Outcomes
- Number of Seroprotected Subjects for Anti-poliovirus Type 1, 2 and 3(Before (PRE) booster vaccination (subjects enrolled before protocol amendment 2))
- Number of Seroprotected Subjects for Anti-D and Anti-T Antibodies(Before (PRE) booster vaccination (subjects enrolled after protocol amendment 2))
- Number of Seropositive Subjects for Anti-Pertussis Toxoid (Anti-PT), Anti-Filamentous Haemagglutinin (Anti-FHA), Anti-Pertactin (Anti-PRN)(Before (PRE) booster vaccination (subjects enrolled before protocol amendment 2))
- Concentrations for Anti-poliovirus Types 1, 2, 3(Before (PRE) booster vaccination (subjects enrolled before protocol amendment 2))
- Concentrations for Anti-Pertussis Toxoid (Anti-PT), Anti-Filamentous Haemagglutinin (Anti-FHA), Anti-Pertactin (Anti-PRN)(Before (PRE) booster vaccination (subjects enrolled before protocol amendment 2))
- Number of Seropositive Subjects for Anti-PT, Anti-FHA, Anti-PRN(Before (PRE) booster vaccination (subjects enrolled after protocol amendment 2))
- Concentration for Anti-poliovirus Types 1, 2, 3(1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2))
- Number of Seropositive Subjects for Anti-pneumococcal (Anti-PNE) Serotypes(1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2))
- Number of Subjects With Booster Response to Anti-pertussis Antigens (Anti-PT, Anti-FHA and Anti-PRN)(1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2))
- Number of Seroprotected Subjects Against Anti-Hepatitis B (Anti-HBs) Antigens(Before (PRE) booster vaccination (subjects enrolled before protocol amendment 2))
- Number of Seroprotected Subjects Against Anti-HBs Antigens(Before (PRE) booaster vaccination (subjects enrolled after protocol amendment 2))
- Concentrations for Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibodies(Before (PRE) booster vaccination (subjects enrolled before protocol amendment 2))
- Number of Seropositive Subjects for Anti-PNE Serotypes(1 month post booster vaccination (POST) (subjects enrolled after protocol amendment 2))
- Number of Subjects Reporting Any Solicited Local Symptom(During the 4-day (Days 0-3) post-vaccination period. (subjects enrolled after protocol amendment 2))
- Anti-Hepatitis B (Anti-HBs) Antibody Concentrations(1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2)))
- Anti-HBs Antibody Concentrations(Before (PRE) booster vaccination (subjects enrolled after protocol amendment 2))
- Concentrations for Anti-poliovirus Types 1, 2 and 3(1 month post booster vaccination (POST) (subjects enrolled after protocol amendment 2))
- Number of Seroprotected Subjects Against Anti-Poliovirus Type 1, 2 and 3(Before (PRE) booster vaccination (subjects enrolled after protocol amendment 2))
- Concentrations for Anti-PRP Antibodies(1 month post booster vaccination (POST) (subjects enrolled after protocol amendment 2))
- Number of Seroprotected Subjects for Anti-polyribosyl-ribitol Phosphate (Anti-PRP)(Before (PRE) booster vaccination (subjects enrolled before protocol amendment 2))
- Concentrations for Anti-pneumococcal (Anti-PNE) Antibodies(1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2))
- Concentrations for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies(Before (PRE) and 1 month post booster vaccination (POST) (subjects enrolled before protocol amendment 2))
- Concentrations for Anti-D and Anti-T Antibodies(Before (PRE) 1 month post booster vaccination (POST) (subjects enrolled after protocol amendment 2))
- Number of Seroprotected Subjects for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies(Before (PRE) booster vaccination (subjects enrolled before protocol amendment 2))
- Concentrations for Anti-PT, Anti-FHA and Anti-PRN(Before (PRE) booster vaccination (subjects enrolled after protocol amendment 2))
- Anti-Hepatitis B (Anti-HBs) Antibody Concentration(Before (PRE) booster vaccination (subjects enrolled before protocol amendment 2))
- Concentration for Anti-poliovirus Type 1, 2 and 3(Before (PRE) booster vaccination (subjects enrolled after protocol amendment 2))
- Number of Seroprotected Subjects for Anti-PRP(Before (PRE) booster vaccination (subjects enrolled after protocol amendment 2))
- Concentrations for Anti-PNE Antibodies(1 month post booster vaccination (POST) (subjects enrolled after protocol amendment 2))
- Number of Subjects Reporting Any Solicited General Symptom(During the 4-day (Days 0-3) post-vaccination period. (subjects enrolled after protocol amendment 2))
- Concentrations for Anti-polyribosyl-ribitol Phosphate Antibodies(Before (PRE) booster vaccination (subjects enrolled after protocol amendment 2)))
- Number of Subjects With Booster Response to Anti-pertussis Antigens(1 month poste booster vaccination (POST) (subjects enrolled after protocol amendment 2))
- Number of Subjects Reporting Any Solicited Local Symptoms(During the 4-day (Days 0-3) post-vaccination period. (subjects enrolled before protocol amendment 2))
- Number of Subjects Reporting Any Solicited General Symptoms(During the 4-day (Days 0-3) post-vaccination period. (subjects enrolled before protocol amendment 2))
- Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)(Within the 31-day (Days 0-30) follow up period after vaccination. (subjects enrolled before protocol amendment 2))
- Number of Subjects Reporting Any Unsolicited AEs(Within the 31-day (Days 0-30) follow up period after vaccination. (subjects enrolled after protocol amendment 2))
- Number of Subjects Reporting Any Serious Adverse Events (SAEs)(During the entire study period (Days 0-30). (subjects enrolled before protocol amendment 2))
- Number of Subjects Reporting Any SAEs(During the entire study period (Days 0-30). (subjects enrolled after protocol amendment 2))